Understanding the Risk Factors for Suicide

Suicide is a complex issue with a variety of risk factors. The strongest indicators of suicide are the presence of a mental disorder, including alcohol-use disorder, and a history of previous suicide attempts. Age and sex also play a role, with the risk increasing with age and men being more likely to complete suicide. Marital status, unemployment, living alone, and chronic illnesses are also associated with an increased risk. It is important to understand these risk factors in order to identify and prevent suicide.

Based on the man’s PHQ-9 score and varied symptoms, it appears that he is suffering from severe depression. According to NICE guidelines, a combination of an antidepressant and psychological intervention is recommended for this level of depression, with an SSRI being the first choice antidepressant. Therefore, citalopram with CBT would be the appropriate treatment in this case. Referral to psychiatry is not necessary at this time. Venlafaxine would be considered as a later option if other antidepressants were ineffective. While fluoxetine is a good first-line antidepressant, it should be combined with a psychological intervention for severe depression. CBT alone is suitable for mild to moderate depression, but for severe depression, an antidepressant in combination with psychological intervention is recommended.

In 2022, NICE updated its guidelines on managing depression and now classifies it as either less severe or more severe based on a patient’s PHQ-9 score. For less severe depression, NICE recommends discussing treatment options with patients and considering the least intrusive and resource-intensive treatment first. Antidepressant medication should not be routinely offered as first-line treatment unless it is the patient’s preference. Treatment options for less severe depression include guided self-help, group cognitive behavioral therapy, group behavioral activation, individual CBT or BA, group exercise, group mindfulness and meditation, interpersonal psychotherapy, SSRIs, counseling, and short-term psychodynamic psychotherapy. For more severe depression, NICE recommends a shared decision-making approach and suggests a combination of individual CBT and an antidepressant as the preferred treatment option. Other treatment options for more severe depression include individual CBT or BA, antidepressant medication, individual problem-solving, counseling, short-term psychodynamic psychotherapy, interpersonal psychotherapy, guided self-help, and group exercise.

Overflow incontinence can be caused by tricyclic antidepressants due to their anticholinergic effects.

The drug class of tricyclic antidepressants, which includes Amitriptyline, can lead to urinary retention and frequent leaking due to their anticholinergic effects. Antimuscarinic drugs can be used to treat urge incontinence, which is caused by detrusor over-activity, while stress incontinence, which occurs when the bladder is under pressure, can result in urine leakage when coughing or laughing.

Tricyclic Antidepressants for Neuropathic Pain

Tricyclic antidepressants (TCAs) were once commonly used for depression, but their side-effects and toxicity in overdose have led to a decrease in their use. However, they are still widely used in the treatment of neuropathic pain, where smaller doses are typically required. TCAs such as low-dose amitriptyline are commonly used for the management of neuropathic pain and the prophylaxis of headache, while lofepramine has a lower incidence of toxicity in overdose. It is important to note that some TCAs, such as amitriptyline and dosulepin, are considered more dangerous in overdose than others.

Common side-effects of TCAs include drowsiness, dry mouth, blurred vision, constipation, urinary retention, and lengthening of the QT interval. When choosing a TCA for neuropathic pain, the level of sedation may also be a consideration. Amitriptyline, clomipramine, dosulepin, and trazodone are more sedative, while imipramine, lofepramine, and nortriptyline are less sedative. It is important to work with a healthcare provider to determine the appropriate TCA and dosage for the individual’s specific needs.

Medical Investigations for Anorexia Nervosa: Which Ones Are Necessary?

When assessing a patient with anorexia nervosa, certain medical investigations may be necessary to evaluate their overall health and identify any potential complications. However, not all investigations are routinely required. Here is a breakdown of some common investigations and when they may be necessary:

Electrocardiogram (ECG): A baseline ECG is important to assess for any cardiovascular instability, including heart rate and QT interval. Electrolyte abnormalities from eating disorders can impact cardiac stability.

24-hour Holter monitor: This investigation may be considered if there is a problem with the baseline ECG or a history of cardiac symptoms such as palpitations.

Chest X-ray (CXR): A CXR is not routinely required unless there is clinical concern of other respiratory symptoms.

Serum prolactin: This investigation is not routinely required unless there is a history of galactorrhoea or amenorrhoea.

Transthoracic echocardiography: This investigation is not routinely required unless there is a clinical history or examination findings to suggest imaging of the heart is required.

When it comes to quickly calming down patients who are exhibiting disruptive behavior, oral lorazepam is typically the first choice. According to NICE guidelines, either intramuscular lorazepam or a combination of intramuscular haloperidol and intramuscular promethazine should be used for rapid tranquilization in patients with acute behavioral disturbances. However, lorazepam is recommended for patients who have not previously taken antipsychotic medication and for those whose heart health is uncertain.

Understanding Psychosis

Psychosis is a term used to describe a person’s experience of perceiving things differently from those around them. This can manifest in various ways, including hallucinations, delusions, thought disorganization, alogia, tangentiality, clanging, and word salad. Associated features may include agitation/aggression, neurocognitive impairment, depression, and thoughts of self-harm. Psychotic symptoms can occur in a range of conditions, such as schizophrenia, depression, bipolar disorder, puerperal psychosis, brief psychotic disorder, neurological conditions, and drug use. The peak age of first-episode psychosis is around 15-30 years.

After a myocardial infarction, Sertraline is the preferred SSRI due to its extensive research in this patient population compared to other SSRIs. It is important to note that the patient may also be taking antiplatelets and should be cautioned about the potential for dyspepsia and gastrointestinal bleeding. Co-prescribing a proton pump inhibitor should be considered.

Selective serotonin reuptake inhibitors (SSRIs) are commonly used as the first-line treatment for depression. Citalopram and fluoxetine are the preferred SSRIs, while sertraline is recommended for patients who have had a myocardial infarction. However, caution should be exercised when prescribing SSRIs to children and adolescents. Gastrointestinal symptoms are the most common side-effect, and patients taking SSRIs are at an increased risk of gastrointestinal bleeding. Patients should also be aware of the possibility of increased anxiety and agitation after starting a SSRI. Fluoxetine and paroxetine have a higher propensity for drug interactions.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning regarding the use of citalopram due to its association with dose-dependent QT interval prolongation. As a result, citalopram and escitalopram should not be used in patients with congenital long QT syndrome, known pre-existing QT interval prolongation, or in combination with other medicines that prolong the QT interval. The maximum daily dose of citalopram is now 40 mg for adults, 20 mg for patients older than 65 years, and 20 mg for those with hepatic impairment.

When initiating antidepressant therapy, patients should be reviewed by a doctor after 2 weeks. Patients under the age of 25 years or at an increased risk of suicide should be reviewed after 1 week. If a patient responds well to antidepressant therapy, they should continue treatment for at least 6 months after remission to reduce the risk of relapse. When stopping a SSRI, the dose should be gradually reduced over a 4 week period, except for fluoxetine. Paroxetine has a higher incidence of discontinuation symptoms, including mood changes, restlessness, difficulty sleeping, unsteadiness, sweating, gastrointestinal symptoms, and paraesthesia.

When considering the use of SSRIs during pregnancy, the benefits and risks should be weighed. Use during the first trimester may increase the risk of congenital heart defects, while use during the third trimester can result in persistent pulmonary hypertension of the newborn. Paroxetine has an increased risk of congenital malformations, particularly in the first trimester.

Understanding Somatoform Disorders: Exploring Possible Diagnoses for a Patient with Medically Unexplained Symptoms

This patient presents with medically unexplained symptoms (MUS), which are collectively known as somatoform disorders. The chronicity and large number of diverse symptoms in this case suggest somatisation disorder, a condition that affects 5-10% of repeat attenders in specialist clinics. Somatisation disorder is more common in women than in men and tends to start in early adulthood. Treatment involves psychological interventions (e.g. CBT) and/or antidepressant medication, but patients are frequently reluctant to engage in these.

Other possible diagnoses for MUS include conversion disorder, hypochondriasis, and undifferentiated somatoform disorder. Conversion disorder presents with neurological symptoms, usually some type of loss of function, while hypochondriasis is associated with a persistent preoccupation to have one or more serious and progressive physical illnesses. In hypochondriasis, the patient puts emphasis on the presence of one (or more) determinate illness and on having it diagnosed. In somatisation disorder, such as in this vignette, the emphasis is on the symptoms (for which the patients seeks a medical explanation), rather than on a specific diagnosis. Undifferentiated somatoform disorder is used when the MUS are multiple and persistent, but the diagnostic criteria for somatisation disorder cannot be fulfilled.

Depression is an important co-morbidity in patients with somatoform disorders, but in this vignette, the combination of physical symptoms and the extensive and complex history of contact with primary and secondary services makes somatisation disorder the most likely diagnosis. It is particularly important to use a patient-centred, empathic interview style with patients with somatoform disorders to ensure they receive the appropriate care and support.

Understanding Movement Disorders Associated with Anti-Psychotic Medication

Anti-psychotic medication can cause a range of movement disorders, including tardive dyskinesia, akathisia, and Parkinsonism. Tardive dyskinesia is a common side-effect of long-term treatment with anti-psychotics, but can also occur with minimal doses. It is characterized by choreoathetoid movements, often starting in the fingers and tongue and becoming more generalized. Treatment is often unsuccessful, but may involve switching to a different medication or using agents such as tetrabenazine or benzodiazepines. Akathisia is an inner feeling of motor restlessness, with voluntary movements such as pacing or rocking. Parkinsonism is characterized by resting tremor, rigidity, and bradykinesia. These movement disorders can be mistaken for other conditions such as Huntington’s or Wilson’s disease, but the association with anti-psychotic medication and the specific symptoms make tardive dyskinesia a more likely option. It is important for healthcare professionals to monitor patients on anti-psychotic medication for these potential side-effects and adjust treatment as necessary.

Antipsychotics are a group of drugs used to treat schizophrenia, psychosis, mania, and agitation. They are divided into two categories: typical and atypical antipsychotics. The latter were developed to address the extrapyramidal side-effects associated with the first generation of typical antipsychotics. Typical antipsychotics work by blocking dopaminergic transmission in the mesolimbic pathways through dopamine D2 receptor antagonism. They are associated with extrapyramidal side-effects and hyperprolactinaemia, which are less common with atypical antipsychotics.

Extrapyramidal side-effects (EPSEs) are common with typical antipsychotics and include Parkinsonism, acute dystonia, sustained muscle contraction, akathisia, and tardive dyskinesia. The latter is a late onset of choreoathetoid movements that may be irreversible and occur in 40% of patients. The Medicines and Healthcare products Regulatory Agency has issued specific warnings when antipsychotics are used in elderly patients, including an increased risk of stroke and venous thromboembolism. Other side-effects include antimuscarinic effects, sedation, weight gain, raised prolactin, impaired glucose tolerance, neuroleptic malignant syndrome, reduced seizure threshold, and prolonged QT interval.

Differentiating Seasonal Affective Disorder from Other Depressive Disorders

Seasonal affective disorder (SAD) is a type of depression that occurs in a regular temporal pattern, typically beginning in autumn or winter and ending in spring or summer. Unlike classic major depression, SAD is characterized by symptoms of hyperphagia, hypersomnia, and weight gain. The cause of SAD is believed to be a malfunction of the light-sensitive hormone melatonin during winter. Treatment involves phototherapy, which exposes individuals to bright light for several hours a day.

Reactive depression, on the other hand, is a subtype of major depression that occurs as a result of an external event, such as a relationship breakdown or bereavement. There is no indication of a stressful life event in the presented vignette.

Bipolar affective disorder is characterized by distinct episodes of depression and mania, which is not evident in the vignette. Dysthymia is a persistent depression of mood that does not fully meet the criteria for a diagnosis of major depression and does not have a definite seasonal variation like SAD.

Finally, double depression occurs when one or more episodes of major depression occur on a background of dysthymia. It is important to differentiate SAD from other depressive disorders to provide appropriate treatment and management.